Introduction {#s0005}
============

Psoriasis is a chronic autoimmune inflammatory disease of the skin that affects 2% to 3% of the population in the United States. Psoriasis is linked to traditional cardiovascular risk factors, such as hypertension (HTN), hyperlipidemia (HLD), obesity, diabetes mellitus (DM), and tobacco use ([@bb0055]). Patients with psoriasis are also at a higher risk of atherosclerotic cardiovascular disease (ASCVD), with up to a 50% greater prevalence of vascular disease than age- and sex-matched controls without psoriasis ([@bb0020], [@bb0080]). Furthermore, psoriasis has been reported to be an independent risk factor for myocardial infarction, and the magnitude of this association is particularly strong among patients with psoriasis who are in their 20s and 30s ([@bb0050]).

Despite the overall high prevalence of psoriasis in the U.S. population, studies evaluating the associations between cardiovascular risk factors and ASCVD in young patients with psoriasis have been relatively small ([@bb0050]). Additionally, specific subtypes of vascular disease, such as venous thromboembolism (VTE), have not been fully studied; sex differences in the rates of ASCVD-associated comorbidities and vascular disease, although speculated ([@bb0030], [@bb0050], [@bb0055], [@bb0070], [@bb0075], [@bb0090], [@bb0115]), have yet to be fully addressed. Therefore, the objectives of this observational study were to identify the burden of cardiovascular risk factors and vascular disease in patients with psoriasis and to explore whether this burden is different between men and women age \< 35 years.

Methods {#s0010}
=======

This was a cross-sectional study based on the Healthcare Cost and Utilization Project's National Inpatient Sample (NIS) data from January 1, 2008 through December 31, 2014. The NIS is a large, de-identified, administrative database with discharge-level coded data from a 20% sample of all hospitals in the United States and includes data from approximately 8 million hospitalizations per year ([@bb0105]). We queried the NIS to identify hospitalized adults age ≥ 20 and \< 35 years with a diagnosis of psoriasis ([@bb0030], [@bb0050]). The upper limit of the age inclusion criterion (\< 35 years) was based on the average age reported in other studies assessing ASCVD risk in young patients with psoriasis ([@bb0035]). The lower limit of the age inclusion criterion (≥ 20 years) was based on American Heart Association publications and figures defining young adults in the National Health and Nutrition Examination Survey population ([@bb0010]).

Patients hospitalized with psoriasis were identified if they were assigned an International Classification of Diseases, Ninth Revision (ICD-9) diagnosis code of 696.1 or 696.0 ([@bb0005]). Young adults hospitalized with psoriasis (n = 18,353 consecutive hospitalizations within the study period) in the NIS were then matched by age, sex, race/ethnicity, and year of admission to patients without psoriasis (n = 55,059) in a 1:3 ratio. In this large administrative database, medical comorbidities associated with ASCVD, including HTN, HLD, DM, obesity, and a history of tobacco use, were defined by their appropriate ICD-9 codes as previously described ([@bb0015]).

The outcome variable of interest was vascular disease, evaluated using a diagnosis of ASCVD or VTE. ASCVD was defined as a composite of any ICD-9 diagnoses of coronary artery disease (CAD), cerebrovascular disease (CVA), or peripheral artery disease (PAD). Key ASCVD subgroups were evaluated separately, including acute myocardial infarction (identified by ICD-9 diagnosis codes for ST-segment \[410.4\] and non-ST-segment elevation myocardial infarction \[410.71\]) and acute ischemic stroke (433.x1, 434.x1, 436, and 437.1). We evaluated the prevalence of VTE by identifying diagnoses of pulmonary embolism (PE; 415.1) and deep vein thrombosis (DVT; 453.40).

Continuous variables were reported as mean (standard deviation), and categorical variables were reported as percentages. Multivariable conditional logistic regression was used to calculate prevalence odds ratios (ORs) and to account for cardiovascular risk factors, including HTN, HLD, obesity, DM, and tobacco use. When examining the association between cardiovascular risk factors and psoriasis, we restricted our sample to patients without ASCVD. This subgroup allowed us to remove potential reverse causation (patients with diagnosed ASCVD may present subsequent modified cardiovascular risk factors) and allow us to explore an earlier phase in the natural history of atherosclerotic disease. We tested for interactions and performed stratified analyses by sex. All analyses were performed in STATA, version14 (StataCorp LP, College Station, TX).

Results {#s0015}
=======

Psoriasis and cardiovascular risk factors {#s0020}
-----------------------------------------

Clinical characteristics of hospitalized young patients with and without psoriasis are shown in [Table 1](#tbl0005){ref-type="table"}. Overall, the mean age was 28.7 ± 4 years, 62% of patients were white, and 58% were women. Obesity, HTN, HLD, DM, and past or present tobacco use were significantly more common in young patients with psoriasis compared with matched patients without psoriasis ([Table 1](#tbl0005){ref-type="table"}). At least one ASCVD risk factor was present in 52% of young patients with psoriasis compared with 30% of the matched patients without psoriasis (all comparison p \< .001).Table 1Clinical characteristics of all patients with psoriasis compared those of matched patients without psoriasisTable 1CharacteristicPsoriasis, n (%)No psoriasis, n (%)[⁎](#tf0005){ref-type="table-fn"}n = 18,353n = 55,059Age, mean (standard deviation), year28.7 ± 428.7 ± 4Men7796 (42)23,388 (42)Race/ethnicity White11,392 (62.0)34,176 (62.0) Black non-Hispanic1245 (6.8)3735 (6.8) Hispanic1660 (9.0)4980 (9.0)Obesity2881 (15.7)3514 (6.4)Hypertension2835 (15.5)4345 (7.9)Hyperlipidemia1010 (5.5)1225 (2.2)Diabetes mellitus1846 (10.1)2976 (5.4)Tobacco use5596 (30.5)9489 (17.2)[^1]

The prevalence and ORs of cardiovascular risk factors in patients with psoriasis are presented in patients without preexisting vascular disease to limit any potential confounding. In the stratified analysis, the prevalence rates of smoking, HLD, and HTN were all higher in men than in women with psoriasis, but women with psoriasis had higher rates of obesity and DM ([Fig. 1](#fig0005){ref-type="fig"}). The association between psoriasis and traditional cardiovascular risk factors was consistently stronger in women than in men across all cardiovascular risk factors ([Fig. 1](#fig0005){ref-type="fig"}).Fig. 1Sex-specific prevalence of cardiovascular risk factors and their association with psoriasis case status among patients without atherosclerotic cardiovascular disease. Unadjusted odds ratio (OR) with confidence interval (95% CI)Fig. 1

Psoriasis and atherosclerotic cardiovascular disease {#s0025}
----------------------------------------------------

Young hospitalized patients with psoriasis had a higher prevalence of ASCVD compared with matched patients without psoriasis (2.2% vs. 1.4%; p \< .01). Additionally, the individual subcomponents of ASCVD, including CAD, CVA, and PAD, were more common in patients with psoriasis ([Fig. 2](#fig0010){ref-type="fig"}). VTE, including DVT, was also more common in patients with psoriasis ([Fig. 2](#fig0010){ref-type="fig"}); however, psoriasis was not associated with a significantly greater frequency of acute PE.Fig. 2Prevalence of vascular disease diagnoses in hospitalized patients with psoriasis compared with that of matched hospitalized patients without psoriasis. ^⁎^p \< .01. ASCVD, atherosclerotic cardiovascular disease (CAD + CVA + PAD); CAD, coronary artery disease; CVA, cerebrovascular disease; DVT, deep vein thrombosis; PAD, peripheral artery disease; PE, pulmonary embolism; VTE, venous thromboembolism (DVT + PE)Fig. 2

When stratified by sex, the prevalence of ASCVD among young patients with psoriasis was 1.8% in women and 2.6% in men. Among the controls, the prevalence of ASCVD was 0.7% in women and 2.3% in men. Overall, the associations between psoriasis and ASCVD were stronger in women with psoriasis than in men ([Table 2](#tbl0010){ref-type="table"}). Compared with women without psoriasis, women with psoriasis had higher odds of ASCVD in the unadjusted analyses (OR: 2.6; 95% confidence interval \[CI; 2.1-3.2\]) and after adjustment for cardiovascular risk factors (adjusted OR: 1.4; 95% CI \[1.1-1.8\]). Similarly, psoriasis was associated with the individual subgroups of CAD, CVA, and PAD among women ([Table 2](#tbl0010){ref-type="table"}). In contrast, men with psoriasis did not have higher odds of ASCVD compared with those without psoriasis in the unadjusted analyses (OR: 1.2; 95% CI \[0.9-1.4\]) or after multivariable adjustment.Table 2Odds of vascular disease in patients with psoriasis compared with matched patients without psoriasis, stratified by sexTable 2WomenPsoriasis, n (%)No psoriasis, n (%)OR (95% CI)Adjusted OR (95% CI)[⁎](#tf0010){ref-type="table-fn"}n = 10,557n = 31,671**Atherosclerotic CVD** Any atherosclerosis191 (1.8)221 (0.7)2.6 (2.1-3.2)1.4 (1.1-1.8) Coronary artery disease89 (0.8)93 (0.3)2.9 (2.1-3.9)1.2 (0.8-1.8) Acute myocardial infarction16 (0.2)17 (0.05)1.9 (1.3-2.9)1.3 (0.6-2.9) Cerebrovascular disease71 (0.7)97 (0.3)2.3 (1.6-3.0)1.5 (1.0-2.0) Acute ischemic stroke27 (0.3)37 (0.1)2.2 (1.3-3.6)1.7 (0.9-2.9) Peripheral artery disease40 (0.4)40 (0.1)3.0 (1.9-4.7)1.9 (1.1-3.2)**Venous thromboembolism** Any venous thromboembolism94 (0.9)142 (0.5)2.0 (1.5-2.6)1.3 (0.9-1.8) Deep vein thrombosis51 (0.5)73 (0.2)2.1 (1.5-3.0)1.8 (1.2-2.7) Pulmonary embolism59 (0.6)88 (0.3)2.0 (1.4-2.8)1.2 (0.8-1.7)**Men**n = 7796n = 23,388**Atherosclerotic CVD** Any atherosclerosis205 (2.6)529 (2.3)1.2 (0.9-1.4)0.9 (0.8-1.10) Coronary artery disease142 (1.8)329 (1.4)1.3 (1.1-1.6)1.0 (0.8-1.2) Acute myocardial infarction51 (0.7)91 (0.4)1.7 (1.2-2.4)1.4 (1.0-1.9) Cerebrovascular disease50 (0.6)152 (0.7)1.0 (0.7-1.4)0.9 (0.6-1.2) Acute ischemic stroke23 (0.3)66 (0.3)1.0 (0.7-1.7)1.0 (0.6-1.6) Peripheral artery disease31 (0.3)72 (0.3)0.9 (0.5-1.4)0.8 (0.5-1.3)**Venous thromboembolism** Any venous thromboembolism83 (1.1)261 (1.1)0.9 (0.7-1.2)0.9 (0.7-1.2) Deep vein thrombosis51 (0.7)141 (0.6)1.1 (0.8-1.5)1.0 (0.7-1.4) Pulmonary embolism42 (0.5)153 (0.7)0.8 (0.6-1.2)0.8 (0.6-1.1)[^2][^3][^4]

Sex differences in the association between psoriasis and VTE were also observed (interaction p \< .01; [Table 2](#tbl0010){ref-type="table"}). In the NIS sample, men had higher rates of VTE compared with women. However, among women, a diagnosis of psoriasis was associated with DVT (subcomponent of VTE; OR: 2.1; 95% CI \[1.5-3.0\]), which remained after multivariable adjustment; no such association was observed among men in the univariate analysis (OR: 1.1; 95% CI \[0.8-1.2\]) or after multivariable adjustment.

Discussion {#s0030}
==========

In this analysis of 18,363 young hospitalized patients diagnosed with psoriasis and 55,059 matched hospitalized controls, we found that the prevalence of cardiovascular risk factors was higher among patients with psoriasis compared with those without psoriasis. We also found increased odds of vascular disease, independent of traditional cardiovascular risk factors. Significant sex differences were also observed, with stronger associations between psoriasis and cardiovascular risk factors, ASCVD, and DVT in women compared with men. To the best of our knowledge, this analysis is one of the largest studies to focus on cardiovascular risk factors as well as ASCVD, VTE and many of its subgroups in young patients with psoriasis and is one of the largest studies to describe sex differences in the association between psoriasis and vascular disease ([@bb0030], [@bb0060], [@bb0065], [@bb0070], [@bb0075], [@bb0115]).

Over the past decade, a number of studies have examined the association between psoriasis and ASCVD ([@bb0050]). In a 2006 study on the risk of ASCVD in patients with psoriasis from the United Kingdom, the odds of ASCVD were highest in 20-year-olds with severe psoriasis ([@bb0050]). Although the increased cardiovascular risk in young adults is well recognized, sex differences in the association between immunologic and vascular diseases remain understudied, and prior literature on this association yielded conflicting results ([@bb0100]). For example, one small study showed that women with psoriasis had a higher prevalence of obesity but lower rates of metabolic syndrome than men with psoriasis ([@bb0110]). Another larger study revealed that young women with psoriasis had three-fold higher rates of metabolic syndrome than young men with psoriasis ([@bb0025]). In other autoimmune diseases, such as rheumatoid arthritis, a small study showed that the relative risk of a cardiac event was several-fold higher in men compared with women with rheumatoid arthritis ([@bb0095]).

In our study, men with and without psoriasis had higher rates of ASCVD and VTE than women, a finding that is consistent with previous studies ([@bb0085]). However, our analysis suggests that psoriasis is independently associated with ASCVD and DVT in young women, but in not men, which is a novel finding. In the present study, women with psoriasis had two- to three-fold higher odds of having a cardiovascular risk factor comorbidity and a higher prevalence of ASCVD or DVT than matched patients without psoriasis. In men, the odds of ASCVD, VTE, or cardiovascular risk factors were increased, but only upwards of two times that of matched without psoriasis, a finding that was largely driven by acute myocardial infarction.

Overall, these data suggest that with inflammatory autoimmune conditions such as psoriasis, complex inflammatory pathways ([@bb0045]) potentially interacting with hormonal factors might be at play and deserve further investigation to explain how sex influences associations between psoriasis, ASCVD, and VTE, particularly among young patients.

There are several limitations to our study. Given the cross-sectional nature of our study, we cannot draw causal conclusions or exclude reverse causality. In any large administrative database, the potential of miscoding of data exists and adds bias and error to the analysis. Psoriasis disease severity, disease duration, and medications were not captured in this administrative database. Therefore, this analysis may have underestimated the association between psoriasis and vascular disease because we could not account for patients who received aspirin, statins, or other medications, which could potentially lower the occurrence of ASCVD. Finally, we chose to evaluate young (defined as \< 35 years of age) hospitalized patients with psoriasis. We selected these age thresholds based on previously reported associations between psoriasis and ASCVD, which are the most pronounced in younger individuals, to permit comparisons with other published studies on young patients with psoriasis and because of the limited data in this population ([@bb0035], [@bb0050]).

Conclusion {#s0035}
==========

This is a hypothesis-generating study, and we found that young adults with psoriasis were more likely to have a diagnosis of cardiovascular disease risk factors, ASCVD, and DVT than young adults without psoriasis. These associations were primarily driven by women with psoriasis. Whether this finding reflects a heightened cardiovascular vulnerability in women with psoriasis compared with men with psoriasis should be explored in future mechanistic studies.

Additionally, traditional risk prediction scores do not adequately capture cardiovascular risk in young patients ([@bb0040]). Our findings help clinicians further recognize the relatively higher rate of ASCVD and ASCVD-related comorbidities in young patients, and may allow earlier initiation of therapeutic interventions designed to reduce ASCVD. Future studies are needed to confirm and explore the higher prevalence of risk factors and ASCVD noted in women with psoriasis and to determine the role of ASCVD risk factor modification therapies in young patients with psoriasis to mitigate vascular disease risk ([@bb0035], [@bb0050]).
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[^1]: Matched by age, sex, race/ethnicity and year of hospital admission. P-values for all other characteristics \< .001.

[^2]: CI, confidence interval; CVD, cardiovascular disease; OR, odds ratio

[^3]: OR adjusted for age, race/ethnicity, and year of hospital admission.

[^4]: Multivariable model adjusted for age, race/ethnicity, obesity, hypertension, diabetes, hyperlipidemia, tobacco use, and year of hospital admission.
